Q-omics provides the consensus-scored RPL23AP35 profile across patient tissues and cancer cell-line models. RPL23AP35 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, RPL23AP35 is differentially expressed in 4, with the highest sampling consensus in KIRC. Additionally, RPL23AP35 RNA expression shows 8,735 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight MESO, KIRC, and GBM as cancer lineages where RPL23AP35 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL23AP35 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL23AP35 survival associations across molecular data types. RPL23AP35 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL23AP35 RNA expression–survival associations across cancer types. High RPL23AP35 expression shows unfavorable associations in MESO, CHOL, UCEC, STAD and OV, but favorable associations in READ. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for RPL23AP35 RNA expression.
This table summarizes RPL23AP35 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL23AP35. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL23AP35 shows lower tumor expression in PAAD and higher tumor expression in KIRC, LIHC and LUAD. The KIRC box plot shows higher RPL23AP35 RNA expression in tumor versus normal tissue (log2 FC = +0.030, t-test p = .008).
This table shows molecular features associated with RPL23AP35 in patient tissues and cancer cell lines. In patient samples, RPL23AP35 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
